Allos has collaborated with Idis, a UK-based global company, to manage the named patient program for FOLOTYN^® (pralatrexate injection) for patients with relapsed or refractory peripheral T-cell lymphoma who reside outside of the United States. A named patient program is a mechanism through which physicians can legally and ethically prescribe investigational or approved drugs for patients prior to their commercial launch.

Licensed healthcare professionals outside the U.S. treating patients with relapsed or refractory peripheral T-cell lymphoma interested in FOLOTYN should contact Idis at:
   
    Tel: +44 (0) 1932 824 123
    Fax: +44 (0) 1932 824 323
    Email: customerservices@idispharma.com

View the press release announcing the Named Patient Program.